Small molecule trail gene induction by normal and tumor cells as an anticancer therapy and tumor cells as an anticancer therapy

Abstract

Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

1 .- 19 . (canceled) 
     
     
         20 . A method of treating a subject having cancer, comprising:
 administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of:   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, hydrate, and/or solvate thereof. 
     
     
         21 . The method of  claim 20 , wherein the subject has a pre-neoplastic hyperproliferation, a cancer in-situ, a neoplasm or a metastasis. 
     
     
         22 . The method of  claim 20 , wherein the cancer is a metastatic cancer. 
     
     
         23 . The method of  claim 20 , wherein the cancer is a grade IV cancer. 
     
     
         24 . The method of  claim 20 , wherein the cancer is a late stage cancer. 
     
     
         25 . The method of  claim 20 , wherein the cancer harbors an oncogenic alteration. 
     
     
         26 . The method of  claim 25 , wherein the oncogenic alteration is inactivation of a tumor suppressor. 
     
     
         27 . The method of  claim 26 , wherein p53 is inactivated. 
     
     
         28 . The method of  claim 26 , wherein PTEN is inactivated. 
     
     
         29 . The method of  claim 25 , wherein the oncogenic alteration is activation of an oncogene. 
     
     
         30 . The method of  claim 29 , wherein EGFR, Her2, and/or KRAS is mutated. 
     
     
         31 . The method of  claim 20 , wherein the cancer is a nervous system cancer. 
     
     
         32 . The method of  claim 31 , wherein the cancer is a central nervous system (CNS) cancer. 
     
     
         33 . The method of  claim 20 , further comprising administering a second therapeutic to the subject, wherein the second therapeutic comprises an anti-cancer agent. 
     
     
         34 . The method of  claim 33 , wherein the anti-cancer agent is a mitotic inhibitor. 
     
     
         35 . The method of  claim 33 , wherein the anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel, and a combination thereof. 
     
     
         36 . The method of  claim 20 , further comprising administering a second therapeutic to the subject, wherein the second therapeutic comprises an anti-angiogenic agent. 
     
     
         37 . The method of  claim 36 , wherein the anti-angiogenic agent is bevacizumab. 
     
     
         38 . The method of  claim 20 , wherein the pharmaceutical composition is administered orally. 
     
     
         39 . The method of  claim 20 , wherein the pharmaceutical composition is administered via a route of administration selected from the group consisting of rectal, nasal, pulmonary, epidural, ocular, otic, intraarterial, intracardiac, intracerebroventricular, intradermal, intravenous, intramuscular, intraperitoneal, intraosseous, intrathecal, intravesical, subcutaneous, topical, transdermal, transmucosal, sublingual, buccal, vaginal, and inhalational routes of administration. 
     
     
         40 . The method of  claim 20 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 
     
     
         41 . The method of  claim 20 , wherein the pharmaceutical composition is a solid dosage form. 
     
     
         42 . The method of  claim 20 , wherein the pharmaceutical composition is a liquid dosage form. 
     
     
         43 . The method of  claim 42 , wherein the liquid dosage form is an injectable liquid.